ArticleInfection & chemotherapy2026
Synergistic Effect of Bacteriophage vB_KpnS_Pey and Antibiotic Combinations against Clinical Carbapenem-Resistant
Article in Infection & chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bacteriophage-Antibiotic Combinations in the Era of Antimicrobial Resistance.Infection & chemotherapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe global rise of antimicrobial resistance, particularly among carbapenem-resistant MATERIALS AND
methodsA total of 30 non-duplicate clinical
resultsTEM revealed that phage vB_KpnS_Pey is a member of the class Caudoviricetes, with an icosahedral head and a long, non-contractile tail. This phage produced clear, halo-form plaques and exhibited lytic activity against 13.3% of CRKP isolates. It showed high EOP against most susceptible strains, a latent period of approximately 30 minutes, and a burst size of 315 plaque-forming units (PFU) per infected cell. The optimal MOI was determined to be 1,000 PFU/colony-forming unit. Combination assays demonstrated phage-antibiotic synergy between vB_KpnS_Pey and subinhibitory concentrations of ciprofloxacin and meropenem, resulting in enhanced bacterial clearance in time-kill experiments. No synergistic effect was observed with gentamicin and colistin.
conclusionThese findings highlight the therapeutic potential of phage vB_KpnS_Pey, particularly when combined with ciprofloxacin and meropenem, as an alternative or combined strategy for treating infections caused by CRKP. Further research is required to fully understand the bacteriophage's mechanisms of action and its associated limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.